Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Lahiru Ranasinghe"'
Publikováno v:
Critical Care Medicine. 50:369-369
Autor:
Lianhua Bai, Genevieve Shano, Molly Karl, Robert H. Miller, Jeffrey A. Cohen, Lahiru Ranasinghe, Eric Garrison, Alex Sargent, Sarah M. Planchon
Publikováno v:
Experimental Neurology. 295:222-232
Mesenchymal stem cells (MSCs) have emerged as a potentially powerful cellular therapy for autoimmune diseases including multiple sclerosis (MS). Based on their success in treating animal models of MS like experimental autoimmune encephalomyelitis (EA
Autor:
Jodi Lyn Layton, Pedro C. Barata, Oliver Sartor, Elisa Ledet, Charlotte Manogue, Patrick Cotogno, Brian E. Lewis, Bryce Raymon Christensen, Lynne Chapman, Peter Steinwald, Lahiru Ranasinghe, Marcus Marie Moses
Publikováno v:
Clinical genitourinary cancer. 18(2)
Background Circulating tumor DNA (ctDNA), which can be assessed by liquid biopsy, can provide valuable genomic information that may affect treatment response in prostate cancer. The aim of this study was to characterize TP53 mutations and treatment h
Publikováno v:
Clinical Pediatrics. 57:1123-1125
Autor:
Lahiru Ranasinghe, Aimee M. Aysenne
Publikováno v:
Spinal Neurosurgery
There are many disease processes which can have clinical manifestations similar to those produced by pathologies requiring surgical intervention. Demyelinating processes, such as multiple sclerosis, neurodegenerative disease such as amyotrophic later
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4cb12904fc8c4e665664976cc72d74da
https://doi.org/10.1093/med/9780190887773.003.0026
https://doi.org/10.1093/med/9780190887773.003.0026
Autor:
Elisa Ledet, Charlotte Manogue, Brian E. Lewis, Allie E. Steinberger, Bruce Bordlee, Patrick Cotogno, Nhan Nguyen, A. Oliver Sartor, Kyle Degeyter, Lahiru Ranasinghe, Pedro C. Barata
Publikováno v:
Cancer treatment and research communications. 20
Prostate cancer patients with liver metastases have a poor prognosis. To date, no study exists investigating the relationship between liver tumor burden and clinical laboratory markers.Metastatic castrate-resistant prostate cancer (mCRPC) patients wi
Background Metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastases have a poor prognosis. No large studies have investigated the clinical and biochemical parameters associated with liver metastases in this population. Mat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3733012b9dfa819df357fb09f82c1eb1
https://europepmc.org/articles/PMC6058331/
https://europepmc.org/articles/PMC6058331/
Autor:
Patrick Cotogno, Elisa Ledet, Charlotte Manogue, Jodi Lyn Layton, A. Oliver Sartor, Brian E. Lewis, Lahiru Ranasinghe, Lynne Chapman, Bryce Raymon Christensen, Leta Ko, Marcus Marie Moses, Peter Steinwald, Joshua Schiff, James Vu
Publikováno v:
Journal of Clinical Oncology. 37:254-254
254 Background: Circulating tumor-derived DNA (ctDNA) is an accessible method for characterizing tumoral alterations. We report ctDNA screenings of mCRPC patients (pts) who have had germline testing. Methods: Guardant360 (Guardant Health, Inc.) asses
Autor:
Jodi Lyn Layton, James Vu, Lahiru Ranasinghe, Marcus Marie Moses, Elisa Ledet, Charlotte Manogue, Patrick Cotogno, A. Oliver Sartor, Brian E. Lewis
Publikováno v:
Journal of Clinical Oncology. 37:245-245
245 Background: Germline mutation testing for metastatic prostate cancer patients creates a potential opportunity to personalize targeted therapies to improve treatment outcomes. The goal of this study was to characterize cancer family history, and e
Autor:
Patrick Cotogno, Peter Steinwald, Brian E. Lewis, A. Oliver Sartor, Jodi Lyn Layton, Bryce Raymon Christensen, Marcus Marie Moses, Lynne Chapman, Pedro C. Barata, Lahiru Ranasinghe, Elisa Ledet, Charlotte Manogue
Publikováno v:
Journal of Clinical Oncology. 37:249-249
249 Background: Genes involved in mCRPC, including the tumor suppressor gene TP53, can be monitored with ctDNA but implications are unclear. Methods: Between 8/6/15 to 9/19/18, patients with mCRPC with available ctDNA genomic data using Guardant360 (